β-cyclodextrin complexes of hydrolyzable adamantanoyl-IUDR prodrugs - radioiodination and biodistribution in mice bearing implanted KBALB tumours

Current Radiopharmaceuticals

Volumn 2, Issue 2, 2009, Pages 137-142

  Xiao Hong, Y ^a,b   Singh, Shradha ^a   Kumar, Piyush ^b   Diakur, Jim ^a,c   Wiebe, Leonard I ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c Canam Bioresearch Inc   (Canada)

Author keywords

cyclodextrin; Adamantanoyl nucleoside prodrugs; Biodistribution; Inclusion complexes; Iododeoxyuridine; KBALB tumours; Nucleosides; Radioiodination

Indexed keywords

5 O (1 ADAMANTANOYL) 5 TRIBUTYLSTANNYL 2' DEOXYURIDINE 2 TBS; 5 O (4 (1 ADAMANTYLCARBAMOYL)BUTYROYL) 5 TRIBUTYLSTANNYL 2' DEOXYURIDINE 3 TBS; BETA CYCLODEXTRIN; IDOXURIDINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE DISTRIBUTION; RADIOIODINATION; THIN LAYER CHROMATOGRAPHY;

EID: 75749099446     PISSN: 18744710     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874471010902020137     Document Type: Article

References (39)

1. Prusoff, W.H. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta, 1959, 32, 295-296.
2. Mathias, A.P.; Fischer, G.A.; Prusoff, W.H. Inhibition of the growth of mouse leukemia cells in culture by 5-iododeoxyuridine. Biochim. Biophys. Acta, 1959, 36, 560-561.
3. Prusoff, W.H. A review of some aspects of 5-iododeoxyuridine and azauridine. Cancer Res., 1963, 23, 1246-1259.
4. Bakhle, Y.S.; Creasey, W.A.; Sartorelli, A.C.; Prusoff, W.H. Some biological and biochemical properties of 5-iodocytosine. Biochem. Pharmacol., 1964, 13, 1249-1259.
5. Eidinoff, M.L.; Cheong, L.; Rich, M.A. Incorporation of unnatural pyrimidine bases into deoxyribonucleic acid of mammalian cells. Science, 1959, 129, 1550-1551.
6. Mak, S.; Till, J.E. Use of I-125-labeled 5-iodo-2'-deoxyuridine for the measurement of DNA synthesis in mammalian cells in vitro. Can. J. Biochem. Physiol., 1963, 41, 2343-2351.
7. 131i-5-iodo-2'-deoxyuridine by malignant tumors in man. Br. J. Cancer, 1991, 63, 134-135.
8. Chiou, R.K.; Dalrymple, G.V.; Baranowska-Kortylewicz J.; Holdeman, K.P.; Schneiderman, M.H.; Harrison, K.A.; Taylor, R.J. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer. J. Urol., 1999, 162, 58-62.
9. 125I-Iodo-2'-deoxyuridine for cancer diagnosis and therapy. J. Nucl. Med. Allied Sci., 1990, 34, 299-303.
10. Mariani, G.; Cei, A.; Collecchi, P.; Baranowska-Kortylewicz, J.; Van den Abbeele, A.D.; Di Luca, L.; Di Stefano, R.; Viacava, P.; Ferdeghini, E.M.; Di Sacco, S.; Salvadori, P.A.; Bevilacqua, G.; Adelstein, S.J.; Mosca, F.; Kassis, A.I. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. J. Nucl. Med., 1993, 34, 1175-1183.
11. 125I]Iodo-'-deoxyuridine in the radiotherapy of brain tumors in rats. J. Nucl. Med., 1998, 39, 1148-1154.
12. 125i]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancer. Ann. N. Y. Acad. Sci., 1993, 698, 204-211.
13. Baranowska-Kortylewicz, J.; Kortylewicz, Z.P.; Hoffman, D.; Dalrymple, G.V. Prodrugs in site-selective delivery of radiopharmaceuticals. Q. J. Nucl. Med., 1997, 41, 12-39.
14. Chakrabarti, M.C.; Paik, C.H.; Carrasquillo, J.A. Preparation and in vitro studies of [125I]IUDR-T101 antibody conjugate. Cancer Biother. Radiopharm., 1999, 14, 91-98.
15. De Clercq, E.; Field, H.J. Antiviral prodrugs the development of successful prodrug strategies for antiviral chemotherapy. Br. J. Pharmacol., 2006, 147, 1-11.
16. Rimoli, M.G.; Avallone, L.; de Caprariis, P.; Galeone, A.; Forni, F.; Vandelli, M.A. Synthesis and iododeoxyuridine of poly(D,Llactic acid)-idoxuridine conjugate. J. Control Release, 1999, 58, 61-68.
17. Bijsterbosch, M.K.; Schouten, D.; van Berkel, T.J. Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry, 1994, 33, 14073-14080.
18. Ita, K.B.; Du Preez, J.; Lane, M.E.; Hadgraft, J.; du Plessis, J. Dermal delivery of selected hydrophilic drugs from elastic liposomes: effect of phospholipid formulation and surfactants. J. Pharm. Pharmacol., 2007, 59, 1215-1222.
19. Szejtli, J. Medicinal applications of cyclodextrins, Medicinal Res. Rev., 1994, 14, 353-386.
20. Wenz, G. Cyclodextrins as building blocks for supramolecular structures and functional units, Angew. Chem. Int. Ed. Engl., 1994, 33, 803-822.
21. Selvam, A.P.; Geetha, D. Ultrasonic studies on lamivudine: betacyclodextrin and polymer inclusion complexes. Pak. J. Biol. Sci., 2008,11, 656-659.
22. Seno, M.; Lin, M.; Iwamoto, K. Chromatic behavior of cyclodextrin complexes of nucleotides, nucleosides and their bases. J. Chromatogr., 1990, 523, 293-299.
23. Eliseev, A.V.; Schneider, H-J. Molecular recognition of nucleotides, nucleosides, and sugars by aminocyclodextrins. J. Am. Chem. Soc., 1994, 116, 6081-6088.
24. Bergeron, R.J.; Channing, M.A.; McGovern, K.A.; Roberts, W.P. Carboxylate anion binding in the cyclohexaamylose cavity: a steric and electronic evaluation. Bioorg. Chem., 1979, 8, 263-281.
25. Hamilton, J.A. Structure of inclusion complexes of cyclomaltpheptaose (cycloheptaamylose): crystal structure of the 1adamantanemethanol adduct. Carbohydr. Res., 1985, 142, 21-37.
26. Eftink, M.R.; Andy, M.L.; Bystrom, K.; Perlmutter, H.D.; Kristol, D.S. Cyclodextrin inclusion complexes: studies in the variation of the size of acyclic guests. J. Am. Chem. Soc., 1989, 111, 6765-772.
27. 1H NMR, J. Org. Chem., 1996, 61, 8307-8309.
28. Yang, X-H.; Singh, S.; Diakur, J.; Wiebe, L.I. Preparation and preliminary evaluation of novel β-cyclodextrin/iudr prodrug formulations. J. Pharm. Pharmaceut. Sci., 2008, 11, 32s-42s.
29. Wigerinck, P.; Kerremans, L.; Claes, P.; Snoeck, R.; Maugdal, P.; De Clercq, E.; Herdewijn, P. Synthesis and antiviral activity of 5thien-2-yl-2'-deoxyuridine analogues. J. Med. Chem., 1993, 36, 538-543.
30. Foulon, C.F.; Zhang, Y.Z.; Adelstein, S.J.; Kassis, A.I. Instantaneous preparation of radiolabeled 5-Iodo-2'-deoxyuridine. Appl. Radiat. Isot., 1995, 46, 1039-1046.
31. 125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy. Nucl. Med. Commun., 2004, 25, 461-468.
32. 131. Int. J. Appl. Radiat. Isotopes, 1965, 16, 337-339.
33. Silvester, D.J.; White, N.D. Preparation of very high specific activity iododeoxyuridine, iodouridine and iodouracil, labelled with iodine-125, -131 or -132. Nature, 1963, 200, 65-66.
34. Prusoff, W.H.; Holmes, W.L.; Welch, A.D. Non-utilization of radioactive iodinated uracil, uridine, and orotic acid by animal tissues in vivo. Cancer Res., 1953, 13, 221-228.
35. Zuo, Z.; Kwon, G.; Diakur, J.; Stevenson, B.; Wiebe, L.I. Flutamide hydroxypropyl- β-cyclodextrin complex: formation, physical characterization and absorption studies using the Caco-2 in vitro model. J. Pharm. Pharmaceut. Sci., 2000, 3, 220-227.
36. Stella, V.J.; Rajewski, R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res., 1997, 14, 556-567.
37. Irie, T.; Uekama, K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci., 1997,86, 147-162.
38. Zuo, Z.; Tam, Y.; Diakur, J.; Wiebe, L.I. Hydroxypropyl- cyclodextrin-flutamide inclusion complex: formulation, oral and intravenous pharmacokinetics of flutamide and the active metabolite, 2-hydroxyflutamide, in the rat. J. Pharm. Pharmaceut. Sci., 2002, 5, 300-306.
39. 125I]iodo-2'-deoxyuridine, a nucleoside-based nitric oxide donor. J. Nucl. Med. Biol. 2005, 32, 641-645.